Development, Implementation, and Evaluation of an Oral Anticancer Management Program

Oral anticancer (OA) agents have become more frequently used for patients diagnosed with cancer. Errors with OA agents can lead to costly and harmful adverse drug reactions and inferior efficacy; however, a standard procedure for prescribing and monitoring OA agents has not been established. An interdisciplinary team of clinicians identified the need for improved safety features in prescribing and monitoring patients prescribed OA agents. The goal of this collaborative project was to develop, implement, and evaluate a standardized program to improve safety for patients newly prescribed OA agents.(c) 2022 Elsevier Inc. All rights reserved.